DK0605501T5 - Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese - Google Patents

Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese

Info

Publication number
DK0605501T5
DK0605501T5 DK92919570T DK92919570T DK0605501T5 DK 0605501 T5 DK0605501 T5 DK 0605501T5 DK 92919570 T DK92919570 T DK 92919570T DK 92919570 T DK92919570 T DK 92919570T DK 0605501 T5 DK0605501 T5 DK 0605501T5
Authority
DK
Denmark
Prior art keywords
cerebellar
palsy
treatment
presynaptic neurotoxin
presynaptic
Prior art date
Application number
DK92919570T
Other languages
English (en)
Other versions
DK0605501T3 (da
Inventor
Herbert Kerr Graham
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10701881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0605501(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK0605501T3 publication Critical patent/DK0605501T3/da
Publication of DK0605501T5 publication Critical patent/DK0605501T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK92919570T 1991-09-24 1992-09-16 Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese DK0605501T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919120306A GB9120306D0 (en) 1991-09-24 1991-09-24 Method and compositions for the treatment of cerebral palsy
PCT/GB1992/001697 WO1993005800A1 (en) 1991-09-24 1992-09-16 Method and compositions for the treatment of cerebral palsy

Publications (2)

Publication Number Publication Date
DK0605501T3 DK0605501T3 (da) 1999-10-25
DK0605501T5 true DK0605501T5 (da) 2007-02-26

Family

ID=10701881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92919570T DK0605501T5 (da) 1991-09-24 1992-09-16 Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese

Country Status (13)

Country Link
US (7) US6395277B1 (da)
EP (1) EP0605501B2 (da)
JP (2) JP3535872B2 (da)
AT (1) ATE178799T1 (da)
AU (1) AU666334B2 (da)
CA (1) CA2119562C (da)
DE (1) DE69228938T3 (da)
DK (1) DK0605501T5 (da)
ES (1) ES2131073T5 (da)
GB (1) GB9120306D0 (da)
GR (1) GR3030418T3 (da)
NO (2) NO312747B1 (da)
WO (1) WO1993005800A1 (da)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
ES2168302T3 (es) * 1993-06-10 2002-06-16 Allergan Inc Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1147776B1 (en) * 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
AU2340299A (en) 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
MXPA03000014A (es) * 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
PT1301213T (pt) * 2000-07-21 2017-04-19 Revance Therapeutics Inc Sistemas de transporte biológico de múltiplos componentes
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
CA2466697C (en) 2001-11-15 2013-09-24 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
WO2003082315A1 (fr) * 2002-03-29 2003-10-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remede contre l'hypermyotonie
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
BRPI0408131A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20050206225A1 (en) * 2004-03-18 2005-09-22 Ford Global Technologies, Llc Method and apparatus for predicting the position of a trailer relative to a vehicle
EP1802250A4 (en) * 2004-05-07 2008-07-02 Phytotox Ltd METHOD FOR TREATING WOUNDS WITH GONYAUTOXINES
EP1796676B1 (en) * 2004-05-07 2016-03-09 Phytotox Limited Transdermal administration of phycotoxins
US20080045889A1 (en) * 2004-07-21 2008-02-21 Gerondale Scott J Botoxo Needle Injector
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
JP2008531725A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． オリゴペプチドの局所適用及び経皮送達のための組成物及び方法
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7608275B2 (en) 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
AU2006315117A1 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
WO2008140594A2 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
EP2114426A4 (en) * 2006-12-29 2010-07-21 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF STABILIZED BOTULINUM TOXINS WITH POLYPEPTIDE FRAGMENTS DERIVED FROM HIV-TAT
CA2672886C (en) * 2006-12-29 2015-02-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
CN102149398B (zh) * 2008-09-11 2013-12-04 I·B·R·以色列生物科技研究有限公司 雪片莲属鳞茎提取物及其用途
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP4697289B2 (ja) * 2008-11-05 2011-06-08 ソニー株式会社 撮像装置、撮像装置の表示制御方法
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
WO2011056684A2 (en) 2009-10-27 2011-05-12 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
BR112014001066A2 (pt) 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014048740A1 (en) 2012-09-25 2014-04-03 Haldor Topsøe A/S Steam reforming catalyst and method of making thereof
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CA2991529C (en) 2015-07-08 2021-01-05 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3801581A4 (en) * 2018-05-24 2022-04-06 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE CONTRACTURES
KR102710632B1 (ko) * 2020-10-07 2024-09-27 주식회사 프로톡스 보툴리눔 독소의 진공 건조 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4234566A (en) * 1979-06-29 1980-11-18 Packman Elias W Antihistamine and methods for use thereof
US4720494A (en) * 1984-11-05 1988-01-19 The Gillette Company Anticholinergic eucatropine esters and antiperspirant use thereof
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
EP0262396A3 (de) 1986-09-20 1989-08-23 Heinz Dipl.-Ing. Hölter Verfahren zum Herstellen von Calciumsulfatdihydrat bei der Rauchgasentschwefelung
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4935969A (en) * 1987-12-02 1990-06-26 Farnsworth Orin J Method and device for the controlled disposal of human waste
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5056291A (en) * 1989-10-19 1991-10-15 Skilland Engineering, Ltd. Modular system for space frame structures
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
JPH06192296A (ja) 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
AU6030494A (en) 1993-01-15 1994-08-15 Associated Synapse Biologics Method for treating myofascial pain syndrome
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
CA2164626C (en) 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
ES2168302T3 (es) * 1993-06-10 2002-06-16 Allergan Inc Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1147776B1 (en) 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2238969T3 (es) 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
TWI243265B (en) 2002-02-27 2005-11-11 Chi Mei Optoelectronics Corp Method for forming a reflection-type light diffuser

Also Published As

Publication number Publication date
NO312747B1 (no) 2002-07-01
US20050112146A1 (en) 2005-05-26
ES2131073T5 (es) 2007-06-16
NO941065D0 (no) 1994-03-23
CA2119562A1 (en) 1993-04-01
DE69228938D1 (de) 1999-05-20
US6448231B2 (en) 2002-09-10
US20050142150A1 (en) 2005-06-30
US7378389B2 (en) 2008-05-27
EP0605501B2 (en) 2006-11-29
DE69228938T3 (de) 2008-01-03
DE69228938T2 (de) 1999-09-23
WO1993005800A1 (en) 1993-04-01
NO941065L (no) 1994-03-23
JP2002097154A (ja) 2002-04-02
NO324159B1 (no) 2007-09-03
JP3535872B2 (ja) 2004-06-07
US20020142010A1 (en) 2002-10-03
ES2131073T3 (es) 1999-07-16
NO20013727L (no) 1994-03-23
GB9120306D0 (en) 1991-11-06
US20080206224A1 (en) 2008-08-28
US20010046962A1 (en) 2001-11-29
US6395277B1 (en) 2002-05-28
US20070224221A1 (en) 2007-09-27
JPH06510779A (ja) 1994-12-01
AU2566492A (en) 1993-04-27
ATE178799T1 (de) 1999-04-15
CA2119562C (en) 2005-02-15
AU666334B2 (en) 1996-02-08
EP0605501B1 (en) 1999-04-14
NO20013727D0 (no) 2001-07-30
DK0605501T3 (da) 1999-10-25
GR3030418T3 (en) 1999-09-30
EP0605501A1 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
DK0605501T5 (da) Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese
DK1322324T3 (da) Fremgangsmåder til behandling af muskelskader
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
CY1108065T1 (el) Χρηση βοτουλινικης τοξινης για την παρασκευη ενος φαρμακου για περιφερικη χορηγηση για θεραπεια πονου που δεν σχετιζεται με μυϊκο σπασιμο ή πονοκεφαλο
ATE215832T1 (de) Botulinumtoxin zur reduktion von migraine - kopfschmerzen
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
DK71387A (da) Terapeutisk middel til behandling af psoriasis
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ATE173263T1 (de) Imidazolochinoxalinonderivate als eaa antagonisten
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
ATE412424T1 (de) Behandlung von druckgeschwüren
ATE147983T1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
ID24561A (id) Pemakaian protein matriks oligomerik kartilaj untuk mengobati artritis rematoid
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
UA50329A (uk) Спосіб лікування первинної бешихи